Results 1 to 10 of about 8,883 (145)

Heterologous prime boost COVID 19 vaccination [PDF]

Infectious Diseases Now, 2022
Heterologous prime boost vaccination is a primary vaccination with different vaccines, most often from different vaccine platforms. It combines the immunological properties of the different vaccines and thereby induces humoral, cellular and, in some cases, mucosal response.
O Launay
exaly   +4 more sources

Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs [PDF]

Vaccines, 2023
Three commercial vaccines are administered in domestic livestock farms for routine vaccination to aid for foot-and-mouth disease (FMD) control in Korea. Each vaccine contains distinct combinations of inactivated serotype O and A FMD virus (FMDV) antigens: O/Manisa + O/3039 + A/Iraq formulated in a double oil emulsion (DOE), O/Primorsky + A/Zabaikalsky ...
Ha-Hyun Kim, Choi-Kyu Park, Jong-Hyeon Park   +2 more
exaly   +5 more sources

Heterologous prime-boost strategies for COVID-19 vaccines. [PDF]

J Travel Med, 2022
AbstractBackground/ObjectiveHeterologous prime–boost doses of COVID-19 vaccines (‘mix-and-match’ approach) are being studied to test for the effectiveness of Oxford (AZD1222), Pfizer (BNT162b2), Moderna (mRNA-1273) and Novavax (NVX-CoV2373) vaccines for COVID in ‘Com-Cov2 trial’ in UK, and that of Oxford and Pfizer vaccines in ‘CombivacS trial’ in ...
Sapkota B, Saud B, Shrestha R, Al-Fahad D, Sah R, Shrestha S, Rodriguez-Morales AJ.   +6 more
europepmc   +4 more sources

Heterologous prime–boost vaccination [PDF]

Current Opinion in Immunology, 2009
An effective vaccine usually requires more than one time immunization in the form of prime-boost. Traditionally the same vaccines are given multiple times as homologous boosts. New findings suggested that prime-boost can be done with different types of vaccines containing the same antigens.
Shan Lu
exaly   +3 more sources

Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2. [PDF]

Vaccine, 2022
Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has proven to be a successful strategy for prevent severe infections. CoronaVac and BNT162b2 are the most used vaccines worldwide, but their use in heterologous vaccination schedules is still subjected to evaluation.Fifty healthy individuals who received heterologous prime-
Rammauro F, Carrión F, Olivero-Deibe N, Fló M, Ferreira A, Pritsch O, Bianchi S.   +6 more
europepmc   +3 more sources

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine. [PDF]

Biomed Pharmacother, 2022
The objective of the present work was to assess the reactogenicity and immunogenicity of heterologous COVID-19 vaccination regimens in clinical trials and observational studies.PubMed, Cochrane Library, Embase, MedRxiv, BioRxiv databases were searched in September 29, 2021. The PRISMA instruction for systemic review was followed.
Nguyen TT, Quach THT, Tran TM, Phuoc HN, Nguyen HT, Vo TK, Vo GV.   +6 more
europepmc   +3 more sources

Heterologous Prime-Boost with Immunologically Orthogonal Protein Nanoparticles for Peptide Immunofocusing. [PDF]

ACS Nano
Abstract Protein nanoparticles are effective platforms for antigen presentation and targeting effector immune cells in vaccine development. Encapsulins are a class of protein-based microbial nanocompartments that self-assemble into icosahedral structures with external diameters ranging from 24 to 42 nm.
Bhattacharya S, Jenkins MC, Keshavarz-Joud P, Bourque AR, White K, Alvarez Barkane AM, Bryksin AV, Hernandez C, Kopylov M, Finn MG.   +9 more
europepmc   +4 more sources

Heterologous prime-boost vaccination against COVID-19: is it safe and reliable? [PDF]

Hum Vaccin Immunother, 2021
Throughout the globe, many nations are struggling to cope with the consecutive waves of the COVID-19. Several vaccines have been employed to overcome this ongoing pandemic and are available as single and double-dose inoculations; however, homologous vaccine efficacy is being reconsidered due to the rapidly emerging SARS-CoV-2 variants.
Choudhary OP, Priyanka, Ahmed JQ, Mohammed TA, Singh I, Rodriguez-Morales AJ.   +5 more
europepmc   +5 more sources

Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine [PDF]

, 2021
Abstract Introduction In August 2021, Thailand imported the BNT162b2 mRNA COVID-19 vaccine. The prioritised group to receive the BNT162b2 vaccine were health professionals. The BNT162b2 vaccine scheduled for healthcare workers were two-dose regimen administered three weeks apart, the third dose ...
Wanlapakorn N, Yorsaeng R, Phowatthanasathian H, Suntronwong N, Kanokudom S, Sudhinaraset N, Poovorawan Y.   +6 more
europepmc   +2 more sources

Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 mRNA [PDF]

, 2021
Abstract Administration of a first dose of the COVID-19 vaccine ChAdOx1 nCoV-19 (Vaxzevria ® , AstraZeneca) is associated with a certain risk for vaccine-induced immune thrombotic thrombocytopenia.
Tenbusch M, Schumacher S, Vogel E, Priller A, Held J, Steininger P, Beileke S, Irrgang P, Brockhoff R, Salmanton-García J, Tinnefeld K, Mijocevic H, Schober K, Bogdan C, Yazici S, Knolle P, Cornely OA, Überla K, Protzer U.   +18 more
europepmc   +2 more sources